Respiratory syncytial virus (RSV) prevention: Perception and willingness of expectant parents in the Netherlands
Guardado en:
| Publicado en: | Vaccine vol. 44 (Jan 12, 2025) |
|---|---|
| Autor principal: | |
| Otros Autores: | , , , , , |
| Publicado: |
Elsevier Limited
|
| Materias: | |
| Acceso en línea: | Citation/Abstract Full Text Full Text - PDF |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3145638209 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 0264-410X | ||
| 022 | |a 1873-2518 | ||
| 024 | 7 | |a 10.1016/j.vaccine.2024.126541 |2 doi | |
| 035 | |a 3145638209 | ||
| 045 | 0 | |b d20250112 | |
| 084 | |a 109921 |2 nlm | ||
| 100 | 1 | |a Harteveld, Lisette M | |
| 245 | 1 | |a Respiratory syncytial virus (RSV) prevention: Perception and willingness of expectant parents in the Netherlands | |
| 260 | |b Elsevier Limited |c Jan 12, 2025 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a BackgroundRespiratory syncytial virus (RSV) is a leading cause of infant respiratory disease. Recent approval of preventive measures like a long-acting monoclonal antibody and a maternal vaccine signals a potential shift in early-life RSV infection control. However, success hinges on acceptance.MethodsWe conducted a cross-sectional survey among pregnant women and partners in the Netherlands, recruited via healthcare professionals, social media platforms, and the 9-Months Fair. The survey assessed willingness and motivation for maternal RSV vaccination and neonatal RSV immunization, including strategy preferences and informational needs.ResultsIn total 1001 pregnant women (mean age: 31.1 years) and their partners (mean age: 33.2 years) completed the survey. On average, they were 24 weeks pregnant at the time, and 54.6 % had no other children yet. The majority was Dutch-born (95.2 % of women); with 68.3 % of women having completed higher education and with overall strong pro-vaccination attitudes (93.9 % of partners intended to vaccinate their expected newborn). The overall acceptability to vaccination and immunization was high, with 87 % of respondents indicating they would (likely) accept both strategies. A positive attitude towards both methods was associated with previous experience with severity of RSV, intention to vaccinate the newborn and parental vaccination status during childhood and current pregnancy. When the choice was given, the majority of participants, in particular those with children and the intention to breastfeed, favoured maternal vaccination over passive immunization of infants (75.3 % of the pregnant and 71.6 % of the partners). A majority of the respondents cited optimal protection for the child and knowledge of RSV as important factors for accepting RSV prophylaxis.ConclusionsWhile most participants would accept both strategies for RSV protection of their infant, a majority, especially those with other children, favoured maternal vaccination, due to concerns about infant safety and awareness of RSV severity. | |
| 651 | 4 | |a Netherlands | |
| 653 | |a Infections | ||
| 653 | |a Parents & parenting | ||
| 653 | |a Respiratory syncytial virus | ||
| 653 | |a Neonates | ||
| 653 | |a Womens health | ||
| 653 | |a COVID-19 vaccines | ||
| 653 | |a Pregnancy | ||
| 653 | |a Vaccines | ||
| 653 | |a Regression analysis | ||
| 653 | |a Immunization (passive) | ||
| 653 | |a Infants | ||
| 653 | |a Disease control | ||
| 653 | |a Monoclonal antibodies | ||
| 653 | |a Social networks | ||
| 653 | |a Questionnaires | ||
| 653 | |a Influenza | ||
| 653 | |a Health care expenditures | ||
| 653 | |a Age | ||
| 653 | |a Disease prevention | ||
| 653 | |a Global health | ||
| 653 | |a Children | ||
| 653 | |a Immunization | ||
| 653 | |a Respiratory diseases | ||
| 653 | |a Prevention programs | ||
| 653 | |a Attitudes | ||
| 653 | |a Education | ||
| 653 | |a Medical research | ||
| 653 | |a Surveys | ||
| 653 | |a Whooping cough | ||
| 653 | |a Newborn babies | ||
| 653 | |a Social | ||
| 700 | 1 | |a van Leeuwen, Lisanne M | |
| 700 | 1 | |a Euser, Sjoerd M | |
| 700 | 1 | |a Smit, Lucy J | |
| 700 | 1 | |a Vollebregt, Karlijn C | |
| 700 | 1 | |a Bogaert, Debby | |
| 700 | 1 | |a van Houten, Marlies A | |
| 773 | 0 | |t Vaccine |g vol. 44 (Jan 12, 2025) | |
| 786 | 0 | |d ProQuest |t Healthcare Administration Database | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3145638209/abstract/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text |u https://www.proquest.com/docview/3145638209/fulltext/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3145638209/fulltextPDF/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |